摘要
目的:探究环磷酰胺联合泼尼松治疗对系统性红斑狼疮患者血清免疫球蛋白、补体C3、C4的影响。方法:选取2016年7月-2019年6月在本院就诊的系统性红斑狼疮患者42例,依据不同治疗方案将其分为对照组与研究组,每组21例。对照组采用泼尼松联合甲氨蝶呤治疗方案,研究组采用泼尼松联用环磷酰胺联合方案,检测分析两组治疗前后免疫球蛋白、补体C3、C4的表达水平、炎性指标的表达水平、临床疗效及不良反应情况。结果:研究组治疗后免疫球蛋白IgM、IgA、IgG的表达水平均低于对照组(P<0.05),补体C3、C4的表达水平均高于对照组(P<0.05),炎性指标(ESR、CRP)的水平均低于对照组(P<0.05),研究组总有效率为95.2%,高于对照组的71.4%(X^2=4.286,P<0.05),研究组不良反应发生率为4.8%,低于对照组的33.3%(X^2=5.559,P<0.05)。结论:临床治疗系统性红斑狼疮采用泼尼松与环磷酰胺的联合方案可降低免疫球蛋白表达水平,提升补体C3、C4表达水平,且疗效甚佳,安全性较高,值得在临床中普及推广及更深层的研究。
Objective:To explore the effect of Cyclophosphamide combined with Prednisone on serum immunoglobulin,complement C3 and C4 in patients with systemic lupus erythematosus.Method:A total of 42 patients with systemic lupus erythematosus who came to our hospital from July 2016 to June 2019 were selected and divided into the control group and the study group according to different treatment plans,21 patients in each group.The control group was treated with Prednisone combined with Methotrexate,while the study group was treated with Prednisone combined with Cyclophosphamide.The expression levels of immunoglobulin,complement C3,C4,inflammatory indicators before and after treatment,clinical efficacy and adverse reactions of two groups were detected and analyzed.Result:After treatment,the expression levels of IgM,IgA and IgG in the study group were lower than those in the control group (P<0.05),the expression levels of complement C3 and C4 in the study group were higher than those in the control group (P<0.05),the levels of ESR and CRP in the study group were lower than those in the control group (P<0.05),and the total effective rate of the study group was 95.2%,which was higher than 71.4% of the control group (X^2=4.286,P<0.05),the incidence of adverse reactions of the study group was 4.8%,which was lower than 33.3% of the control group (X^2=5.559,P<0.05).Conclusion:The combination of Prednisone and Cyclophosphamide in the clinical treatment of systemic lupus erythematosus can reduce the expression level of immunoglobulin and improve the expression level of complement C3 and C4,with a good efficacy and high safety,which is worthy of popularization and further research in clinical practice.
作者
徐水明
杨清媛
胡宏凯
XU Shuiming;YANG Qingyuan;HU Hongkai(Ganzhou Municipal Hospital,Ganzhou 341000,China)
出处
《中国医学创新》
CAS
2020年第6期66-69,共4页
Medical Innovation of China
